LianBio (LIAN)

[Triple nickle]

Hmmm bunch of buy volume this morning

[IVANj]

Looks like they gave it out cash divy at 4.8/share

[Awl416]

Holy smokes

[ipo_dude]

Here she goes

[Biggeoff]

Seems like a whale is loading. Every. Single. Dip. Has been bought up

[MiamiGent]

Yes, it is trading under book, with a pipeline.
More tomorrow..

[smokey1]

$ 5.60 p/s cash. They had $267 million at the end of June. They probably burned $17 for Q3 That leave $250 million at (9/30/23) Now another $350 from BMY.That's $600 million divided by 107 million shares =$5.60p/s.Is that correct?

[MiamiGent]

LIAN While INM has been a meteor this morning, let's look under the hood of a smooth rising runner, LIANBIO

https://stockcharts.com/h-sc/ui?s=LIAN

$3.05 +1.6604 (+119.45%)
As of Oct-24-202310:51:20 AM ET

LIANBIO had news:

Why LianBio Stock Is Ripping Higher Today
BENZINGA

LianBio (NASDAQ:LIAN) shares are trading higher Tuesday after the company announced an agreement with Bristol Myers Squibb (NYSE:BMY) to purchase LianBio's exclusive rights to develop and commercialize mavacamten in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.

The Details:

Under the terms of the agreement, LianBio will receive a one-time payment of $350 million. The agreement also releases LianBio from payment obligations of up to $127.5 million in remaining milestone payments under the MyoKardia license agreement as MyoKardia, Inc. is now a wholly owned subsidiary of Bristol Myers Squibb.

"Over the past three years, we have worked in close collaboration with BMS to bring mavacamten to patients in Asia," said Yizhe Wang, Ph.D., CEO of LianBio. "The LianBio team executed a successful clinical development and regulatory strategy in our territories and has built robust launch infrastructure in anticipation of mavacamten's potential approval in China next year."

Shares of LIAN are up on heavy trading volume after the announcement. According to data from Benzinga Pro, more than 25.3 million shares have already been traded in the session, compared to the stock's 100-day average of 198 thousand shares.

So this solid news, a "real" play

LIAN has very substantial Institutional ownership, 75%

It had $279M in ready cash as of June 30th 10Q

Appears to have an annual burn of $82M but with a wire transfer of $350M coming, dilution is not likely.

Trading below book, even with today's run.

This could go on a while...

[TheFinalCD]

SOLD LAST 3.45 WHAT A GREAT TRADING STOCK

EVEN THOUGH HAD ME NERVOUS @ 2.13

[TheFinalCD]

$LIAN 2.13 WAS MY LOW BUY JUST SOLD 3.12

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082745

[Monksdream]

ONE can always ask FINRA to blue sheet trades

[TheFinalCD]

THE WASH TRADING OUR GOV LETS HAPPEN IS UNREAL

[TheFinalCD]

$LIAN 2.40 Overall Risk Low https://dilutiontracker.com/app/search/LIAN

[Monksdream]

It probably is

[TheFinalCD]

$LIAN NEWS

Under the terms of the agreement, LianBio will receive a one-time payment of $350 million. In addition, LianBio will be released from payment obligations of up to $127.5 million in remaining milestone payments under the MyoKardia license agreement.

https://www.globenewswire.com/news-release/2023/10/24/2765435/0/en/LianBio-Enters-into-Agreement-with-Bristol-Myers-Squibb-for-Mavacamten-in-China-and-Other-Asian-Markets.html

[Awl416]

LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets

[Monksdream]

LIAN under $2